Document:

ex_184040.htm

 

 

Exhibit 10.1

 

Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified by the term “{redacted}”.

 

 

	
			AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

				
			1. CONTRACT ID CODE

				
			PAGE OF PAGES

			
	 	 	
			1

				
			4

			
	
			2. AMENDMENT/MODIFICATION NO.

			P00004

				
			3. EFFECTIVE DATE

			See Block 16C

				
			4. REQUISITION/PURCHASE REQ. NO.

				
			5. PROJECT NO. (If applicable)

			ASPR-19-03461

			 

			
	
			6. ISSUED BY                                                                                                                      CODE

				
			ASPR-BARDA

				
			7. ADMINISTERED BY (If other than Item 6)                                                                   CODE

				
			 

			
	
			ASPR-BARDA

			200 Independence Ave., S.W.

			Room 640-G

			Washington DC 20201

				 	 
	 	
			 

			
	
			8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

			 

			SIGA TECHNOLOGIES, INC. 1385150

			Attn: Daniel Luckshire

			SIGA TECHNOLOGIES, INC.

			31 East 62nd street

			NEW YORK, NY 100658446

				
			(x) 

				
			9A. AMENDMENT OF SOLICITATION NO.

			
	 	 	9B. DATED (SEE ITEM 11)
	 	 	
			 

			
	 	
			x

				
			10A. MODIFICATION OF CONTRACT/ORDER NO.

			HHSO100201800019C

			
	 	 	
			10B. DATED (SEE ITEM 13)

			09/10/2018

			
	
			CODE 1385150

				
			FACILITY CODE

				 	 

 

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

☐The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers     ☐ is extended.     ☐ is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing

Items 8 and 15, and returning ______ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By

separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE

RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR

OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided

each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	
			12. ACCOUNTING AND APPROPRIATION DATA (If required)

			See Schedule

				 
	
			13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

			 

				 
	
			CHECK ONE

				
			A.THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

				 
	 	 	 
	 	
			B.THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

				 
	
			X

				
			C.THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

			 FAR 43.103 (a) By Mutual Agreement between the parties

				 
	
			 

				
			D.OTHER (Specify type of modification and authority)

				 
	
			E.IMPORTANT: Contractor☐is not☒is required to sign this document and return _____1___ copies to the issuing office.

				 
	
			14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

			Tax ID Number: 13-3864870

			DUNS Number: 932651516

			The purpose of this modification P00004 is to revise Article B.2 to:

			(a)   Remove Phase 3 multiple dose study, and add TPOXX-phosphate binders

			study conduct and PFR formulation development to CLIN 0001

			(b) Extend the Base Period of Performance (CLIN 0001) from 09/09/2023 through 12/31/2025

			(c) Revise the verbiage for the TPOXX-phosphate binders study and PFR

			formulation development in CLIN 0007 to ensure there are no overlaps

			in activities between CLIN 0001 and CLIN 0007

			See the attached Statement of Work for further details

			 

			Continued ...

			Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

				 
	
			15A. NAME AND TITLE OF SIGNER (Type or print)

			 

			Dennis E. Hruby, CSO

				
			16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

			 

			George J. Keane

			
	
			15B. CONTRACTOR/OFFEROR

			/s/ Dennis E. Hruby

			(Signature of person authorized to sign)

				
			15C. DATE SIGNED

			27 Jan 2020

				
			16B.UNITED STATES OF AMERICA

			/s/ George J. Keane

			(Signature of Contracting Officer)

				
			16C. DATE SIGNED

			2/4/20

			

 

	Previous edition unusable   	 	STANDARD FORM 30 (REV. 11/2016)
	 	 	Prescribed by GSA FAR (48 CFR) 53.243

                                                                                                                                                                                                                                                                                                                              

 

 

	
			CONTINUATION SHEET

				
			REFERENCE NO. OF DOCUMENT BEING CONTINUED

			HHSO100201800019C/P00004

				
			Page of

			
	 	 	
			2

				
			4

			
	
			NAME OF OFFEROR OR CONTRACTOR

			SIGA TECHNOLOGIES, INC. 1385150

			
	
			ITEM NO.

			(A)

				
			SUPPLIES/SERVICES

			(B)

				
			QUANTITY

			(C)

				
			UNIT

			(D)

				
			UNIT PRICE

			(E)

				
			AMOUNT

			(F)

			
	 	
			All other terms and conditions remain unchanged as a result of this modification

			Period of Performance: 09/10/2018 to 09/09/2028

			-

			PSC: AN13 NAICS: 541714 HHS/BARDA COR is David Simon, David.Simon@hhs.gov, (202) 260-1101

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

			 

				 	 	 	 

                                                                                                                                                                                                                                                                                                                                                                                     

	NSN 7540-01-152-8067   	 	 OPTIONAL FORM 336 (4-86)   
	 	 	 Sponsored by GSA
	 	 	 FAR (48 CFR) 53.110

                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                 

 

Statement of Work

 

SIGA will furnish all the necessary services, qualified personnel, materials, supplies, equipment, facilities, transportation and travel not otherwise provided by the USG as required to fulfill the programmatic objectives. SIGA has completed the New Drug Application and has manufactured and delivered a total of 2 million courses of nonparenteral (oral) smallpox antiviral formulation to the USG, and has advanced the early stage development activities for parenteral (IV) formulation. The overall goal of this proposal is to complete the late-stage development of the parenteral formulation and to supply the USG with both parenteral and nonparenteral formulations.

 

The scope of this proposal includes the following activities:

	 	
			1.

				
			CLIN0001 (Base): {redacted}

			

	 	
			2.

				
			CLIN0002 (Base): Immediate delivery of approximately 23,000 treatment courses of oral formulation

			

	 	
			3.

				
			CLIN0003 (Base): {redacted}

			

{Added to Contract: Procurement of BDS for manufacturing of IV TPOXX}

	 	
			4.

				
			CLIN0004 (Base): Manufacture/fill/package/stability IV TPOXX

			

	 	
			5.

				
			CLIN0005 (Base): Storage of packaged IV TPOXX in VMI for up to 5 years

			

	 	
			6.

				
			CLIN0006 (Base): Delivery of up to 20,000 treatment courses of IV TPOXX to SNS

			

	 	
			7.

				
			CLIN0007 (Option): {redacted}

			

	 	
			8.

				
			CLIN0008 (Option): Post-marketing field study, maintenance and support of NDA and electronic IND and NDA submissions for IV formulation, and relabeling (if needed)

			

	 	
			9.

				
			CLIN0009 (Option): Delivery of up to 363,070 treatment courses of oral TPOXX to SNS

			

	 	
			10.

				
			CLIN0010 (Option): Delivery of up to 363,070 treatment courses of oral TPOXX to SNS

			

	 	
			11.

				
			CLIN0011 (Option): Delivery of up to 363,070 treatment courses of oral TPOXX to SNS

			

	 	
			12.

				
			CLIN0012 (Option): Delivery of up to 363,072 treatment courses of oral TPOXX to SNS

			

	 	
			13.

				
			CLIN0013 (Option): Procurement of BDS for manufacturing of IV TPOXX

			

	 	
			14.

				
			CLIN0014 (Option): Storage of BDS for manufacturing of IV TPOXX

			

	 	
			15.

				
			CLIN0015 (Option): Manufacture/fill/package/stability IV TPOXX

			

	 	
			16.

				
			CLIN0016 (Option): Storage of packaged IV TPOXX in VMI for up to 5 years

			

	 	
			17.

				
			CLIN0017 (Option): Delivery of up to 64,000 treatment courses of IV TPOXX to SNS

			

	 	
			18.

				
			CLIN0018 (Option): Procurement of BDS for manufacturing of IV TPOXX

			

	 	
			19.

				
			CLIN0019 (Option): Storage of BDS for manufacturing of IV TPOXX

			

	 	
			20.

				
			CLIN0020 (Option): Manufacture/fill/package/stability IV TPOXX

			

	 	
			21.

				
			CLIN0021 (Option): Storage of packaged IV TPOXX in VMI for up to 5 years

			

	 	
			22.

				
			CLIN0022 (Option): Delivery of up to 64,000 treatment courses of IV TPOXX to SNS

			

	 	
			23.

				
			CLIN0023 (Option): Procurement of BDS for manufacturing of IV TPOXX

			

	 	
			24.

				
			CLIN0024 (Option): Storage of BDS for manufacturing of IV TPOXX

			

	 	
			25.

				
			CLIN0025 (Option): Manufacture/fill/package/stability IV TPOXX

			

	 	
			26.

				
			CLIN0026 (Option): Storage of packaged IV TPOXX in VMI for up to 5 years

			

	 	
			27.

				
			CLIN0027 (Option): Delivery of up to 64,000 treatment courses of IV TPOXX toSNS

			

	 	
			28.

				
			CLIN0028 (Option): Delivery of up to 50,000 treatment courses of IV TPOXX to SNS

			

 

A detailed plan indicating how each aspect of the Statement of Objectives shall be accomplished, information pertaining to project organization, staffing, and management, including the management and coordination of consultant and sub-contractor effort, and Deliverables Table are located in the technical section of the proposal. Where applicable, the technical proposal denotes activities already accomplished against a given objective. The project plan, Work Breakdown Structure, and critical milestones are located in the Integrated Master Project Plan.

 

END OF MODIFICATION 0004 TO HHSO100201800019Cqrhc-ex101_6.htm

Exhibit 10.1

  

 NOTE 

 

		
	
SBA Loan # 
	
44231072-07  

	
SBA Loan Name 
	
Quest Resource Management Group LLC  

	
Date 
	
April 30, 2020  

	
Loan Amount 
	
$1,408,000.00  

	
Interest Rate 
	
1.00%  

	
Borrower 
	
Quest Resource Management Group LLC 

	
Operating 

Company 
	
N/A 

	
Lender 
	
BMO Harris Bank National Association  

 

	
 
	
1.
	
PROMISE TO PAY: 
	
 

In return for the Loan, Borrower promises to pay to the order of Lender the amount of $1,408,000.00, interest on the unpaid principal balance, and all other amounts required by this Note. 

	
 
	
2.
	
DEFINITIONS: 
	
 

“Collateral” means any property taken as security for payment of this Note or any guarantee of this Note. 

“Guarantor” means each person or entity that signs a guarantee of payment of this Note. 

“Loan” means the loan evidenced by this Note. 

“Loan Documents” means the documents related to this loan signed by Borrower, any Guarantor, or anyone who pledges collateral. 

“SBA” means the Small Business Administration, an Agency of the United States of America. 

 

 

	
 
	
1.
	
PAYMENT TERMS: 
	
 

Borrower must make all payments at the place Lender designates. The payment terms for this Note are: 

	
	
Maturity: This Note will mature in 2 years and 0 months from date of Note. 

 

Repayment terms: 

 

The interest rate is 1% per year. The interest rate may only be changed in accordance with SOP 50 10. 

 

Borrower must pay principal and interest payments of $79,235.13 every month, beginning 7 months from the date of the Note; payments must be made on the same day as the date of the Note in the months they are due. 

 

Lender will apply each installment first to pay interest accrued to the day Lender receives the payment, then to bring principal current, then to pay any late fees, and will apply any remaining balance to reduce principal. 

 

Loan Prepayment: 

 

Notwithstanding any provision in this Note to the contrary: 

 

Borrower may prepay this Note. Borrower may prepay 20 percent or less of the unpaid principal balance at any time without notice. If Borrower prepays more than 20 percent and the Loan has been sold on the secondary market, Borrower must: 

 

a.Give Lender written notice; 

 

b.Pay all accrued interest; and 

 

c.If this prepayment is received less than 21 days from the date Lender receives the notice, pay      an amount equal to 21 days' interest from the date lender receives the notice, less any         interest accrued during the 21 days and paid under subparagraph b., above. 

 

If Borrower does not prepay within 30 days from the date Lender receives the notice, Borrower must give Lender a new notice. 

 

All remaining principal and accrued interest is due and payable 2 years and 0 months from date of Note. 

 

Late Charge: If payment on this Note is more than10 days late, Lender may charge Borrower a late fee of up to 5.00 % of the unpaid portion of the regularly scheduled payment. 

 

2 of 7

 

   

SBA Form 147 (06/03/02) Version 4.1 

1. DEFAULT: 

Borrower is in default under this Note if Borrower does not make a payment when due under this Note, or if Borrower or Operating Company: 

	
 
	
A.
	
Fails to do anything required by this Note and other Loan Documents; 
	
 

	
 
	
B.
	
Defaults on any other loan with Lender; 
	
 

	
 
	
C.
	
Does not preserve, or account to Lender’s satisfaction for, any of the Collateral or its proceeds; 
	
 

	
 
	
D.
	
Does not disclose, or anyone acting on their behalf does not disclose, any material fact to Lender or SBA; 
	
 

	
 
	
E.
	
Makes, or anyone acting on their behalf makes, a materially false or misleading representation to Lender or SBA; 
	
 

	
 
	
F.
	
Defaults on any loan or agreement with another creditor, if Lender believes the default may materially affect Borrower’s ability to pay this Note; 
	
 

	
 
	
G.
	
Fails to pay any taxes when due; 
	
 

	
 
	
H.
	
Becomes the subject of a proceeding under any bankruptcy or insolvency law; 
	
 

	
 
	
I.
	
Has a receiver or liquidator appointed for any part of their business or property; 
	
 

	
 
	
J.
	
Makes an assignment for the benefit of creditors; 
	
 

	
 
	
K.
	
Has any adverse change in financial condition or business operation that Lender believes may materially affect Borrower’s ability to pay this Note; 
	
 

	
 
	
L.
	
Reorganizes, merges, consolidates, or otherwise changes ownership or business structure without Lender’s prior written consent; or 
	
 

	
 
	
M.
	
Becomes the subject of a civil or criminal action that Lender believes may materially affect Borrower’s ability to pay this Note.  
	
 

 

	
 
	
2.
	
LENDER’S RIGHTS IF THERE IS A DEFAULT: 
	
 

Without notice or demand and without giving up any of its rights, Lender may: 

A.Require immediate payment of all amounts owing under this Note; 

B.Collect all amounts owing from any Borrower or Guarantor; 

C.File suit and obtain judgment; 

D.Take possession of any Collateral; or 

E.Sell, lease, or otherwise dispose of, any Collateral at public or private sale, with or without advertisement.  

 

	
 
	
3.
	
LENDER’S GENERAL POWERS: 
	
 

Without notice and without Borrower’s consent, Lender may: 

 

  3 of 7 

SBA Form 147 (06/03/02) Version 4.1 

	
 
	
A.
	
Bid on or buy the Collateral at its sale or the sale of another lienholder, at any price it chooses; 
	
 

	
 
	
B.
	
Incur expenses to collect amounts due under this Note, enforce the terms of this Note or any other Loan Document, and preserve or dispose of the Collateral. Among other things, the expenses may include payments for property taxes, prior liens, insurance, appraisals, environmental remediation costs, and reasonable attorney’s fees and costs. If Lender incurs such expenses, it may demand immediate repayment from Borrower or add the expenses to the principal balance; 
	
 

	
 
	
C.
	
Release anyone obligated to pay this Note; 
	
 

	
 
	
D.
	
Compromise, release, renew, extend or substitute any of the Collateral; and E. Take any action necessary to protect the Collateral or collect amounts owing on this Note. 
	
 

	
 
	
4.
	
WHEN FEDERAL LAW APPLIES: 
	
 

When SBA is the holder, this Note will be interpreted and enforced under federal law, including SBA regulations. Lender or SBA may use state or local procedures for filing papers, recording documents, giving notice, foreclosing liens, and other purposes. By using such procedures, SBA does not waive any federal immunity from state or local control, penalty, tax, or liability. As to this Note, Borrower may not claim or assert against SBA any local or state law to deny any obligation, defeat any claim of SBA, or preempt federal law.  

 

	
 
	
5.
	
SUCCESSORS AND ASSIGNS: 
	
 

Under this Note, Borrower and Operating Company include the successors of each, and Lender includes its successors and assigns.  

 

	
 
	
6.
	
GENERAL PROVISIONS: 
	
 

	
 
	
A.
	
All individuals and entities signing this Note are jointly and severally liable. 
	
 

	
 
	
B.
	
Borrower waives all suretyship defenses. 
	
 

	
 
	
C.
	
Borrower must sign all documents necessary at any time to comply with the Loan Documents and to enable Lender to acquire, perfect, or maintain Lender’s liens on Collateral. 
	
 

	
 
	
D.
	
Lender may exercise any of its rights separately or together, as many times and in any order it chooses. Lender may delay or forgo enforcing any of its rights without giving up any of them. 
	
 

	
 
	
E.
	
Borrower may not use an oral statement of Lender or SBA to contradict or alter the written terms of this Note. 
	
 

	
 
	
F.
	
If any part of this Note is unenforceable, all other parts remain in effect. 
	
 

	
 
	
G.
	
To the extent allowed by law, Borrower waives all demands and notices in connection with this Note, including presentment, demand, protest, and notice of dishonor. Borrower also waives any defenses based upon any claim that Lender did not obtain any guarantee; did not obtain, perfect, or maintain a lien upon Collateral; impaired Collateral; or did not obtain the fair market value of Collateral at a sale. 
	
 

 

  4 of 7 

SBA Form 147 (06/03/02) Version 4.1 

1. STATE-SPECIFIC PROVISIONS: 

 

   

The following provision applies when a borrower is a resident of WISCONSIN:  

Each Borrower who is married represents that this obligation is incurred in the interest of his or her marriage or family. 

  

The following Confession of Judgment provision applies when a borrower is a resident of DELAWARE:  

WARRANT OF ATTORNEY/CONFESSION OF JUDGMENT. In addition to any other remedies Lender may possess, Borrower knowingly, voluntarily and intentionally authorizes any attorney to appear on behalf of Borrower, from time to time, in any court of record possessing jurisdiction over this Note and to waive issuance and service of process and to confess judgment in favor of Lender against Borrower, for the unpaid principal, accrued interest, accrued charges, reasonable attorney fees and court costs and such other amount due under this Note.  

 

The following Confession of Judgment provision applies when a borrower is a resident of MARYLAND:  

WARRANT OF ATTORNEY/CONFESSION OF JUDGMENT. Borrower authorizes an attorney to appear in a court of record and confess judgment, without process, against Borrower in favor of Lender for all indebtedness owed in connection with the loan, including but not limited to service charges, other charges and reasonable attorney's fees.  

 

The following Confession of Judgment provision applies when a borrower is a resident of OHIO:  

WARRANT OF ATTORNEY/CONFESSION OF JUDGMENT. In addition to any other remedies Lender may possess, Borrower knowingly, voluntarily and intentionally authorizes any attorney to appear on behalf of Borrower, from time to time, in any court of record possessing jurisdiction over this Note and to waive issuance and service of process and to confess judgment in favor of Lender against Borrower, for the unpaid principal, accrued interest, accrued charges, reasonable attorney fees and court costs and such other amount due under this Note. WARNING: BY SIGNING THIS PAPER YOU GIVE UP YOUR RIGHT TO NOTICE AND COURT TRIAL. IF YOU DO NOT PAY ON TIME, A COURT JUDGMENT MAY BE TAKEN AGAINST YOU WITHOUT YOUR PRIOR 

KNOWLEDGE AND THE POWERS OF THE COURT CAN BE USED TO COLLECT FROM YOU REGARDLESS OF ANY CLAIMS YOU MAY HAVE AGAINST THE CREDITOR WHETHER FOR RETURNED GOODS, FAULTY GOODS, FAILURE ON HIS PART TO COMPLY WITH THE AGREEMENT OR ANY OTHER CAUSE.  

 

The following Confession of Judgment provision applies when a borrower is a resident of PENNSYLVANIA: 

WARRANT OF ATTORNEY/CONFESSION OF JUDGMENT. Borrower irrevocably authorizes and empowers the prothonotary, any attorney or any clerk of any court of record, upon default, to appear for and confess judgment against Borrower for such sums as are due and/or may become due under this Note including costs of suit, without stay of execution, and for attorney's fees and costs as set forth in this Note and knowingly, voluntarily and intentionally waives any and all rights Borrower may have to notice and hearing under the state and federal laws prior to entry of a judgment. To the extent permitted by law, Borrower releases all errors in such proceedings. If a copy of this Note, verified by or on behalf of the holder shall have been filed in such action, it shall not be necessary to file the original Note as a warrant of attorney. The authority and power to appear for and confess judgment against Borrower shall not be exhausted by the initial exercise thereof and may be exercised as often as the holder shall find it necessary and desirable and this Note shall be a sufficient warrant for such authority and power.  

 

 

  

  5 of 7 

SBA Form 147 (06/03/02) Version 4.1 

 

The following Confession of Judgment provision applies when a borrower is a resident of VIRGINIA: IMPORTANT NOTICE: THIS INSTRUMENT CONTAINS A CONFESSION OF JUDGMENT PROVISION WHICH CONSTITUTES A WAIVER OF IMPORTANT RIGHTS YOU MAY HAVE AS A DEBTOR AND ALLOWS THE CREDITOR TO OBTAIN A JUDGMENT AGAINST YOU WITHOUT ANY FURTHER NOTICE. WARRANT OF ATTORNEY/CONFESSION OF JUDGMENT. In addition to

any other remedies Lender may possess, Borrower knowingly, voluntarily and intentionally authorizes to appear on behalf of Borrower, from time to time, in the District Court of Alexandria, Virginia and to waive issuance and service of process and to confess judgment in favor of Lender against Borrower, for the unpaid principal, accrued interest, accrued charges, reasonable attorney fees and court costs and such other amount due under this Note. The following Oral Agreements Disclaimer provision applies when the borrower is a resident of MISSOURI: Oral or unexecuted agreements or commitments to loan money, extend credit or to forbear from enforcing repayment of a debt including promises to extend or renew such debt are not enforceable, regardless of the legal theory upon which it is based that is in any way related to the credit agreement. To protect you (Borrowers(s)) and us (Creditor) from misunderstanding or disappointment, any agreements we reach covering such matters are contained in this writing, which is the complete and exclusive statement of the agreement between us, except as we may later agree in writing to modify it.

The following Oral Agreements Disclaimer provision applies when the borrower is a resident of MISSOURI: Oral or unexecuted agreements or commitments to loan money, extend credit or to forbear from enforcing repayment of a debt including promises to extend or renew such debt are not enforceable, regardless of the legal theory upon which it is based that is in any way related to the credit agreement. To protect you (Borrowers(s)) and us (Creditor) from misunderstanding or disappointment, any agreements we reach covering such matters are contained in this writing, which is the complete and exclusive statement of the agreement between us, except as we may later agree in writing to modify it.

The following Oral Agreements Disclaimer provision applies when the borrower is a resident of OREGON: UNDER OREGON LAW, MOST AGREEMENTS, PROMISES AND COMMITMENTS MADE BY [BENEFICIARY]/ US CONCERNING LOANS AND OTHER CREDIT EXTENSIONS WHICH ARE NOT FOR PERSONAL, FAMILY, OR HOUSEHOLD PURPOSES OR SECURED SOLELY BY GRANTOR'S/BORROWER'S RESIDENCE MUST BE IN WRITING, EXPRESS CONSIDERATION AND BE SIGNED BY [AN AUTHORIZED REPRESENTATIVE OF BENEFICIARY]/US TO BE ENFORCEABLE.

The following Oral Agreements Disclaimer provision applies when the borrower is a resident WASHINGTON:

Oral agreements or oral commitments to loan money, extend credit, or to forbear from enforcing repayment of a debt are not enforceable under Washington law.

The following provision applies when the borrower is a resident of ALASKA:

The Mortgagor or Trustor (Borrower) is personally obligated and fully liable for the amount due under the Note. The Mortgagee or Beneficiary (Lender) has the right to sue on the Note and obtain a personal judgment against the Mortgagor or Trustor for the satisfaction of the amount due under the Note either before or after a judicial foreclosure of the Mortgage or Deed of Trust as under AS 09.45.170-09.45.220.

The following Oral Agreements Disclaimer provision applies when the borrower is a resident of IOWA: IMPORTANT: READ BEFORE SIGNING. The terms of this agreement should be read carefully because only those terms in writing are enforceable. No other terms or oral promises not contained in this written contract may be legally enforced. You may change the terms of this agreement only by another written agreement.

The following Oral Agreements Disclaimer provision applies when the borrower is a resident of UTAH: This is a final expression of the agreement between the creditor and debtor and the written agreement may not be contradicted by evidence of any alleged oral agreement.

 

  6 of 7 

SBA Form 147 (06/03/02) Version 4.1 

1.BORROWER’S NAME(S) AND SIGNATURE(S):

By signing below, each individual or entity becomes obligated under this Note as Borrower.

		
	
Quest Resource Management Group LLC  

 ___________________________________________________ 

Signature of Authorized Representative of Borrower/Borrower 

/s/ Laurie L. Latham

___________________________________________________ 

Name of Authorized Representative of Borrower 
	
 

 

 

 

April 30, 2020

 ______________________ 

Date 

 

CFO

_______________________ 

Title 

 

  7 of 7 

SBA Form 147 (06/03/02) Version 4.1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]